Metropolis Healthcare Presents Alarming Findings of PLAC Test

Press Release

Metropolis2

33 % samples between 30 - 50 years at high risk of developing heart attack
and 36% samples at moderate risk

Hyderabad, September 28th, 2015: Cardiovascular disease emerged as India’s top killer around the mid-1980s and ever since, it has been a growing threat. According to the recent WHO data, one in 3 Indians succumb to cardiovascular diseases and an increasing number of individuals less than 40 years are developing cardiac disease or risk factors associated with cardiac disease. It is important to detect these conditions for early intervention and the good news is that a battery of tests is available to make early screening and intervention possible.

Metropolis Healthcare Ltd, a multinational pathology chain recently conducted a pan India PLAC study on over 300 samples. Out of the 311 samples analysed, over 30% between the age group 30 and 50 years were found to be at a high risk for developing coronary heart disease.

Overview: It has been observed that 50% heart attacks occur in patients with normal cholesterol levels. Traditional markers of cardiovascular risk such as total cholesterol levels, HDL, LDL VLDL and triglycerides tell physicians very little about acute risk of heart attack simply because these tests do not include any inflammatory markers. So, individuals with moderate risk as determined by these standard tests may actually be at a greater risk of developing heart attack or stroke than predicted.

What is the PLAC Test?

The PLAC test or the Lp-PLA2 (Lipoprotein associated phospholipase A2) test is a simple blood test that predicts the risk of heart attack & stroke in the next 5 years. It is a simple test which can tell you how healthy your heart is and measures the enzyme activity of Lp-PLA2 level in the body.

Why PLAC Test?

It has been observed that individuals with normal cholesterol levels and higher levels of PLAC are at a greater risk of developing heart attack. Likewise, individuals with high cholesterol but low levels of PLAC are at a lower risk of developing heart attack and continue to lead a normal life. Hence the PLAC test acts as an independent marker of heart health which is imperative of your cholesterol levels.

How does the PLAC test work?

Heart attacks occur when the supply of oxygen rich blood is cut off to the heart. Over the years, when plaque (wax like substance that is made up of fat and cholesterol) accumulates in the arteries carrying blood to the heart, it results in heart disease. When plaque ruptures it leads to heart attack. LP-PLA2 is an enzyme that is involved in the formation of a plaque that is prone to rupture. Thus people with increased levels of blood level of Lp-PLA2 are at a greater risk of developing heart attack and stroke.

Who should undergo this test?

In December 2014, the US FDA has approved this as a screening test in all adults with no history of heart disease. Apart from this, Lp-PLA2 (PLAC) test is recommended in 4 major guidelines.

AACE Guideline 2012 | European Society of Cardiology 2012 | AHA / ASA Guideline 2011 (American Heart Association / American Stroke Association) | AACF Guideline 2010 (American College of Cardiology Foundation)

metropolis-cervical-cancer-jan-2015

Metropolis Healthcare Study

Metropolis Healthcare Ltd, a multinational chain of pathology laboratories; has become one of the few laboratories in India to offer PLAC Test. Metropolis conducted a random pan India study on 311 samples for PLAC Test. Out of 311 samples analyzed, about 29% between the age group of 30 and 50 years were found to be at high risk of developing Coronary Heart Disease (CHD). Below are the complete findings.

“It is not a surprise that over 50% heart attacks occur in people with normal cholesterol levels because majority of heart attacks are caused by plaque ruptures. Basically plaques are made of fats and cholesterol found in blood. But a simple cholesterol test does not give any indication on the level of vascular inflammation or does not measure the activity of a rupture prone plaque. This is a simple blood test to assess your heart health.” says Dr. Sonali Kolte, General Manager – Medico Marketing, Metropolis Healthcare Ltd.

metropolis PLAC chart 1
metropolis PLAC chart 2
metropolis PLAC chart 3

About Metropolis Healthcare Ltd
At Metropolis, what we believe is what we say and what we say is what we do. Being empathetic to our customers and being committed to their needs is in our DNA. Metropolis has grown to harness a culture that is open, synergistic, progressive and scientific in nature.

We are the Pathology Specialists delivering over 30 million tests a year, catering to more than 10,000 Laboratories, Hospitals, Nursing homes and 2,00,000 Consultants. With 34 years of experience in delivering accurate reports, Metropolis has earned the reputation of being India's most respected and only multinational chain of diagnostic centers with presence in UAE, Sri Lanka, South Africa, Kenya, Mauritius and Ghana.

Driven to make a difference, our wide network includes 130 state-of-art Laboratories across India with over 1000 collection centers, processing over 4500 varieties of tests and supported by an efficient team of more than 3500 people. Equipped with cutting edge technology, innovative work equipment, expansive logistics network and rigorous processes, Metropolis ensures and delivers precision and accuracy in every single test; each time, every time.

In the last 10 years, Metropolis has expanded into new service lines like Clinical Trials, Hospital Lab Management, Home Health Services, Preventive Health Check-ups and Corporate & Wellness Solutions. Metropolis is at the forefront in adopting cutting edge technologies and services that contribute new revenue streams and has positioned the company on the pedestal it is today.

Today, we are one of the few laboratories that has received the CAP (College of American Pathologists), accreditation, the global gold standard in Laboratory Accreditation. We have also received the NABL Accreditation (National Accreditation Board for testing and Calibration Laboratories). In addition, we also adhere to CLIA (Clinical Laboratory Improvement Amendments) program and follow the guidelines laid by GCP and GLP. Our unit in South Africa is accredited by SANAS (South African National Accreditation System is the only accreditation body approved by South African Government).

At Metropolis, we believe in unveiling the inner health of individuals and this motto extends to our corporate social responsibility activities as well. Giving back to the society is embedded in the value system of Metropolis and we believe and aim to bring about a positive change in the nation. Metropolis has been at the forefront in conducting impactful camps and driving numerous workshops for different sections of the society for the past 3 decades. We partner with societies, corporates, educational institutions, government bodies, NGOs, wellness foundations and a host of other organisations to make a difference to the lives we touch. Our camps and awareness workshops emphasize on preventive healthcare and early screening of diseases. Some of our most recent associations include Epilepsy Foundation, Hep Free India, Mumbai Traffic Police, Kishori Foundation, Children of Blind School and JeevanJyot Cancer Trust.

Metropolis has been awarded numerous accolades like the ‘Best Diagnostic Company of the year’ by Modern Medicare in 2006 and ‘Best Diagnostic Company of the Year’ in 2010 by Frost & Sullivan. Metropolis was also bestowed with ‘Best IT Integration in Customer Service Management’ at the e-Health World Expo 2011. Metropolis was also honoured with the ‘Quality Brand Award’ by NEHRDO in 2012. Metropolis won the ‘CMO Asia Award’ for Best IT practices in Healthcare in 2012. Metropolis recently bagged the ‘India’s most promising brand award’ at Global Indian Excellence Summit 2014 held in London. Metropolis Healthcare is led by Ameera Shah, Managing Director & CEO. An International & National Award winner, she was conferred with ‘The Young entrepreneur of the Year Award’ by GE in 2006 and ‘The Young Achiever of the Year Award’ at the CMO Asia Awards in 2011. She was also the recipient of the prestigious ‘Young Entrepreneur of the Year Award’ in 2011 organised by Entrepreneur India and Bloomberg. She has been honoured with ‘Exemplary Women Leadership award’ at the World Women Leadership and Congress awards 2014. Recently she has been chosen as one of the most respected leaders under 40 years by Economic Times & Spencer Stuart (2014). Metropolis recently being awarded “Diagnostic Services Company of the year” at Vccircle Healthcare awards 2015.

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Press Releases, Press Releases Featured 2 and tagged , . Volume: .

One Comment

  1. Suresh Amin
    Posted Oct 2015 at 3:04 am | Permalink

    This is a good way to market a test. Sample size is small and the article should also give international comparative study including good and bad – since there is no perfect test there will be limitation to any test
    As they say there is conflict of interest in any published work
    Dr Suresh Amin

Post a Comment

You must be logged in to post a comment.